The Somascan® Assay: biomarker discovery to delivery
Watch the webinar now
ABSTRACT
The SomaScan® Assay is a proteomic platform that uses single-stranded DNA engineered with aromatic hydrocarbon side chains for binding to protein targets. The SomaScan® Assay has been used to identify signals as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.
Sheri K. Wilcox, Ph.D
Scientific Liaison and Technical Services, SomaLogic Inc
Sheri K. Wilcox is Senior Director, Scientific Liaison and Technical Services, at SomaLogic, Inc. in Boulder, Colorado. She received her B.S. in Chemistry from Vanderbilt University in Nashville, Tennessee, in 1993 and her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California, in 1999. She completed two years of post-doctoral studies at Pharmacia and Upjohn in Kalamazoo, Michigan, and then joined SomaLogic, Inc. in 2001, where she has been contributing to the generation and utility of novel protein affinity reagents based on Slow-Off rate Modified Aptamers (SOMAmer® reagents) for over 19 years.
More webinars
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.